Publication-quality outputs

The graphics your reviewer
actually wants to see

PRISMA 2020 flow diagrams (Page et al., BMJ 2021), forest plots with summary diamonds and heterogeneity stats, LogFrame matrices, and lifetime QR-verifiable certificates — all rendered live as scalable SVG. Use the live tools, or take these as reference for your manuscripts.

PRISMA 2020 flow Forest plot LogFrame Certificate Tier Badges DAG Sample Size Search Strategy
PRISMA Flow Forest Plot LogFrame Certificate Tier Badges DAG Sample Size Search Strategy
Page et al. BMJ 2021;372:n71

PRISMA 2020 Flow Diagram

The canonical four-stage flow diagram for systematic reviews and meta-analyses. Identification → Screening → Eligibility → Included. Every PRISMA-compliant manuscript reproduces this exact structure. Below: an editable, downloadable rendering you can drop into your manuscript today.

  • Records identified — from each database with counts
  • Records removed before screening — duplicates, ineligibles, automation
  • Screening — titles/abstracts + full-text excluded with reasons
  • Included — final synthesis pool with reasons for exclusion
Build yours in AI SRMA Suite Read PRISMA 2020 guide
Identification Screening Eligibility Included Records identified from: PubMed (n = 1,247) Embase (n = 894) Cochrane CENTRAL (n = 312) Scopus (n = 521) Web of Science (n = 478) Total: n = 3,452 Records removed before screening: Duplicates (n = 612) Marked ineligible by automation tools (n = 184) Other reasons (n = 42) Total removed: n = 838 Records screened n = 2,614 Records excluded n = 2,401 (title/abstract) Reports sought for retrieval n = 213 → 207 retrieved Reports not retrieved n = 6 (no full text) Reports assessed for eligibility n = 207 Reports excluded (n = 165): Wrong population (n = 58) Wrong intervention (n = 41) Wrong outcome (n = 32) Wrong study design (n = 19) No comparator (n = 12) Duplicate report (n = 3) Studies included in review n = 42 (reports = 42) → Meta-analysis: n = 38

Reference: Page MJ et al. The PRISMA 2020 statement. BMJ 2021;372:n71

Study Events / Total RR [95% CI] Weight 0.2 0.5 1.0 2.0 5.0 Favours intervention Favours control Rolnik 2017 (ASPRE) 13/798 vs 35/822 0.38 [0.20, 0.74] 18.4% Bujold 2010 9/247 vs 21/256 0.41 [0.18, 0.94] 12.1% Caron 2017 16/532 vs 31/540 0.51 [0.28, 0.91] 15.3% Park 2019 18/411 vs 28/418 0.61 [0.34, 1.09] 14.2% Mendoza 2015 10/198 vs 14/201 0.70 [0.32, 1.55] 8.4% Singh 2020 (India) 22/619 vs 30/612 0.72 [0.45, 1.16] 16.8% Hassan 2018 14/295 vs 16/298 0.85 [0.48, 1.50] 10.6% Garcia 2014 (small) 7/156 vs 6/162 1.20 [0.55, 2.62] 4.2% Random-effects pooled estimate 109/3,256 vs 181/3,309 0.57 [0.42, 0.78] 100.0% Heterogeneity: τ² = 0.04; Q = 9.8, df = 7, p = 0.20; I² = 28.6% (low) Test for overall effect: Z = 3.51, p < 0.001 · Prediction interval: 0.33 – 0.98 Eight studies of low-dose aspirin for prevention of pre-eclampsia in nulliparous women — mock data, illustrative only.

DerSimonian-Laird random-effects model · Cochrane Handbook v6.4 · Reported per PRISMA 2020 + SAMPL

Cochrane Handbook v6.4

Forest Plot

The visual signature of every meta-analysis. Each row is one study with its risk ratio + 95% CI; the size of the box reflects the study's weight in the pooled estimate. The red diamond at the bottom is the random-effects summary — its width is the pooled 95% CI; if it crosses the null line, the result is not statistically significant.

  • Logarithmic x-axis — symmetric around the null (RR = 1)
  • Study boxes — sized by inverse-variance weight
  • Summary diamond — DerSimonian-Laird random-effects
  • Heterogeneity — τ², Cochran Q, I² with interpretation band
  • Prediction interval — likely effect in a new study
Generate yours in AI SRMA Suite Open RoB suite
EU · FCDO · UN donor format

LogFrame Matrix

The canonical 4×4 logical framework used by every bilateral donor, UN agency, and major foundation. Goal · Purpose · Outputs · Activities across the rows; Narrative · OVIs · Means of Verification · Assumptions across the columns. Below: a live preview of what the wizard produces.

  • Vertical logic — IF activities → THEN outputs → THEN purpose → THEN goal
  • Horizontal logic — every row has indicators + verification + assumptions
  • Donor variants — EU/FCDO 4×4 · UNDP 5-row · 1-page compact (auto-recommended)
Open the LogFrame wizard View all 13 frameworks
Level Narrative summary OVIs MoV Assumptions
Goal
Long-term impact		 Reduced maternal morbidity from hypertensive disorders in Bilaspur district. MMR from hypertensive disorders: 22 → ≤15/100,000 by 2030 MDSR annual report; HMIS extract State policy stable; no new contraindications emerge.
Purpose
Project outcome		 ≥70% of eligible nulliparous ANC attendees receive aspirin prophylaxis before 16 wks GA. % screened at booking: 8% → ≥70% by 2029. % screen-positive initiating aspirin <16 wks: 4% → ≥85%. ANC register audit (Q); pharmacy data Coverage translates to reduced PE per ASPRE 2017.
Outputs
Deliverables		 O1: SOP adopted district-wide. O2: 300 providers trained. O3: Supply chain assured. O4: HMIS revised. SOP approved by M6. Post-training pass rate ≥95%. Stock ≥95% across PHCs every Q. DHO order copy; attendance records; PHC stock audits Training time released; community accepts intervention.
Activities
What you do		 SOP development · TOT cascade training · Procurement + buffer stock · Supportive supervision · KAP campaign. Inputs / Budget: Personnel ₹38L · Training ₹14L · Procurement ₹22L · M&E ₹9L · Indirect ₹8.8L. Total ₹96.8 lakhs. Quarterly progress reports; financial audit Funds disbursed on schedule; political continuity.

EU/FCDO 4×4 variant · downloads as editable Word .doc with A4 margins

URN

Utkarsh Research Network

URN Academy · AISRMA programme

◆

Certificate

of Completion — AISRMA — Systematic Review & Meta-Analysis

This is to certify that

Dr Paramjot Panda

has successfully completed the URN Academy AISRMA — Systematic Review & Meta-Analysis programme, covering all 32 lessons across 4 levels:
Foundations · Screening & selection · Extraction & Risk of Bias · Meta-analysis & manuscript.

The programme is aligned with PRISMA 2020 · Cochrane Handbook v6.4 · RoB 2 · ROBINS-I · QUADAS-2 · GRADE. The learner has demonstrated competence in Protocol writing, search-strategy design, dual-independent screening, data extraction, RoB 2 · ROBINS-I · QUADAS-2 assessment, meta-analytic synthesis (fixed + random effects), heterogeneity (I² · τ²), publication-bias assessment, GRADE certainty rating, and manuscript preparation.

◆
Dr Paramjot Panda
Founder & Growth Catalyst
 Verify
Scan to verify
Dr Jyoti Ranjan Mohanty
Founder

Certificate ID: URN-AISRMA-20260101-PANDA01 · Issued: 01 January 2026 · Lifetime — does not expire

This is the actual certificate generator — same HTML the engine emails on course completion. Sample shown for our founder Dr Paramjot Panda; logo, dual signatures, and QR code are all real (the QR resolves to the live verification page when scanned).

Try the verification page

Lifetime · QR-verifiable

URN Academy Certificate

Issued automatically when a learner completes all 4 levels of any URN Academy course (Research Methods · Data Analysis · HNA · AISRMA). Each carries a unique ID, dual signatures, and a QR code that resolves to a public verification page — so any employer or institution can confirm authenticity in one scan.

  • Tier ladder — Bronze (L1) → Silver (L1-2) → Gold (L1-3) → Platinum (full course)
  • Auto-emailed at every tier with a shareable SVG badge
  • Public verification — anyone can validate via the QR or ID
  • Lifetime validity — never expires
See certificate showcase Start AISRMA course
Bronze · Silver · Gold · Platinum

Tier Badges

Every URN Academy course has a 4-tier ladder. Bronze unlocks when you finish Level 1; Silver after L1-2; Gold after L1-3; Platinum is the full Certificate of Completion shown above. Each badge is auto-emailed as a shareable SVG — LinkedIn-ready, prints clean at any size, never goes pixelated.

  • Auto-issued when you cross a level boundary (one per learner, per course, per tier)
  • Themed per course — Research Methods (green) · Data Analysis (indigo) · HNA (pink) · AISRMA (sky-blue)
  • SVG output — scales infinitely, opens in any browser, sharable on LinkedIn / portfolio sites
  • Same engine as certificate — sample badges below show our founder Dr Panda's AISRMA progression
Start an AISRMA tier See public showcase
URN ACADEMY Bronze AWARDED TO Dr Paramjot Panda AISRMA — Systematic Review & Meta-Analysis Level 1 complete UTKARSH RESEARCH NETWORK • 2026 utkarshresearchnetwork.in

Bronze · Level 1

Foundations done

URN ACADEMY Silver AWARDED TO Dr Paramjot Panda AISRMA — Systematic Review & Meta-Analysis Levels 1 & 2 complete UTKARSH RESEARCH NETWORK • 2026 utkarshresearchnetwork.in

Silver · Levels 1-2

Screening done

URN ACADEMY Gold AWARDED TO Dr Paramjot Panda AISRMA — Systematic Review & Meta-Analysis Levels 1, 2 & 3 complete UTKARSH RESEARCH NETWORK • 2026 utkarshresearchnetwork.in

Gold · Levels 1-3

Extraction & RoB done

The 4-tier progression

★

BRONZE

L1

→
★

SILVER

L1-2

→
★

GOLD

L1-3

⟹
★

PLATINUM

Certificate

Every course follows this ladder. Platinum unlocks the QR-verifiable Certificate of Completion shown in Panel 4.

Live SVG output from urnBadgeSVG() — same engine that emails badges when learners cross a level boundary

Causal inference

Directed Acyclic Graphs

A DAG is a picture of your causal hypothesis. Once it's on paper, the bias paths you have to close become obvious — and the variables you must not adjust for (mediators) become equally obvious. URN's free in-browser DAG builder produces these.

  • Exposure → Outcome — the causal effect you're estimating
  • Confounders — variables that cause both; must adjust
  • Mediators — sit on the causal path; must not adjust if total effect is the target
  • Colliders — adjusting opens a bias path; must avoid
  • Backdoor criterion — the formal rule for which paths to block
Maternal age Prior HTN U (genetic) Aspirin (low-dose) Placental blood flow Pre- eclampsia CAUSAL (mediated) CAUSAL (via mediator) confounder → confounder → backdoor (unmeasured) Backdoor paths through Maternal age + Prior HTN are blocked by adjustment. The unmeasured genetic backdoor remains — quantify via sensitivity analysis.
Exposure Outcome Confounder (measured) Mediator Unmeasured (U) Causal / measured path Backdoor bias path

Example: low-dose aspirin → pre-eclampsia, adjusting for maternal age and prior hypertension. Placental blood flow is a mediator (don't adjust). Unmeasured genetic predisposition is a residual backdoor — sensitivity analysis required.

Study power

Sample Size Calculator

Plug in your expected effect, alpha, and power. Get the per-arm sample size with formula transparency — so the IEC reviewer can verify the math, and you can defend your number under questioning.

  • → Two-proportion test for binary outcomes (default shown)
  • → Continuous outcomes — two-sample t-test mode
  • → Survival / time-to-event — log-rank test mode
  • → Dropout inflation automatically applied
Formula · two-proportion z-test nper arm = (zα/2 √2·p̄·(1−p̄) + zβ √p₁(1−p₁) + p₂(1−p₂))² / (p₁ − p₂)²
        = (1.96 √2·0.095·0.905 + 0.842 √0.12·0.88 + 0.07·0.93)² / (0.12 − 0.07)²
        = (0.811 + 0.341)² / 0.0025   =   ≈ 530 per arm
nadjusted = 530 / (1 − 0.15)   =   ≈ 624 per arm
Per arm 624 after 15% dropout inflation
Total enrolment 1,248 two arms · 1 : 1 allocation
Power achieved 80% at α = 0.05, two-sided

Illustrative — based on the aspirin-in-pregnancy use case used elsewhere on this page. Replace the inputs with your own numbers in the live calculator.

PRISMA-S 2021

Boolean Search Strategy

A reproducible search is the spine of every systematic review. Stack concept blocks with AND, expand each block with OR + MeSH + free-text — then translate to every database (PubMed, Embase, Cochrane CENTRAL, Scopus, Web of Science) without losing fidelity.

  • → One concept block per PICO element
  • → MeSH + Emtree + free-text in every block
  • → Truncation + wildcards for spelling variants
  • → Cross-database translation tracked + exported per PRISMA-S
1 Population — nulliparous pregnant women 128,492 hits

("Pregnancy"[Mesh] OR pregnan*[tiab] OR gestation*[tiab] OR antenatal[tiab] OR "first pregnan*"[tiab]) AND ("Parity"[Mesh] OR nulliparous[tiab] OR nullipara*[tiab] OR primigravida*[tiab])

2 Intervention — low-dose aspirin 42,107 hits

("Aspirin"[Mesh] OR aspirin[tiab] OR "acetylsalicylic acid"[tiab] OR ASA[tiab]) AND (low-dose[tiab] OR "60 mg"[tiab] OR "75 mg"[tiab] OR "81 mg"[tiab] OR "100 mg"[tiab] OR "150 mg"[tiab])

3 Outcome — pre-eclampsia 38,560 hits

"Pre-Eclampsia"[Mesh] OR "Hypertension, Pregnancy-Induced"[Mesh] OR "pre-eclampsia"[tiab] OR "preeclampsia"[tiab] OR "pregnancy hypertension"[tiab] OR "gestational hypertension"[tiab] OR "HELLP"[tiab]

4 Study design — RCT filter 1.2M hits

"Randomized Controlled Trial"[Publication Type] OR "randomized"[tiab] OR "randomised"[tiab] OR "controlled trial"[tiab] OR "placebo"[tiab] OR "double blind"[tiab] OR "Random Allocation"[Mesh]

Final hits · PubMed

2,847

After deduplication across 5 databases: 3,452 unique records

Reproducibility

Search executed: 14 March 2026 · Re-run schedule: monthly · PRISMA-S checklist: 14 of 14 items reported

Live preview from the AI SRMA Suite search builder. Concept-by-concept hit counts let you spot over- or under-coverage before submitting. Build your own search.

All four, free to use right now.

No login wall on the reference pages. Sign-in only when you start a draft you want to save or download.

Frameworks Wizards RoB Suite AI SRMA Suite Project Workspaces